Cartesian Therapeutics (FRA:1S70) Inventories, Raw Materials & Components: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1S70 Cartesian Therapeutics Inc FRA:1S70
27 GF Score
Price €6.60
GF Value €0.23
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Cartesian Therapeutics Inventories, Raw Materials & Components?

Cartesian Therapeutics FRA:1S70 +2.33% 27 Inventories, Raw Materials & Components is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:1S70 with a GF Score™ of 27/100 and a GF Value™ of €0.23 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Cartesian Therapeutics's inventories, raw materials & components for the quarter that ended in Mar. 2026 was €0.00 Mil.

Cartesian Therapeutics Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Cartesian Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cartesian Therapeutics Inventories, Raw Materials & Components Chart

Cartesian Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cartesian Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:1S70
27GF Score
Cartesian Therapeutics Inc FRA:1S70
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cartesian Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €0.00 Mil mean?
Cartesian Therapeutics (FRA:1S70) has a Inventories, Raw Materials & Components of €0.00 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Cartesian Therapeutics and its competitors.
Is Cartesian Therapeutics' Inventories, Raw Materials & Components too high?
Cartesian Therapeutics' current Inventories, Raw Materials & Components is €0.00 Mil. Overall, Cartesian Therapeutics has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cartesian Therapeutics' Inventories, Raw Materials & Components compare to LYEL and ALXO?
Cartesian Therapeutics' Inventories, Raw Materials & Components of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Cartesian Therapeutics and its competitors. Cartesian Therapeutics's current Inventories, Raw Materials & Components is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cartesian Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cartesian Therapeutics (FRA:1S70) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.23, compared to a current price of €6.60 — trading 2769.6% above its estimated fair value. The current Inventories, Raw Materials & Components is €0.00 Mil. Cartesian Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Cartesian Therapeutics (FRA:1S70), the current Inventories, Raw Materials & Components is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cartesian Therapeutics (FRA:1S70) Overvalued in 2026?

Based on GuruFocus' analysis, Cartesian Therapeutics stock appears to be overvalued. The current stock price of €6.60 is trading 2769.6% above its estimated GF Value™ of €0.23. GuruFocus considers Cartesian Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:1S70:

  • Inventories, Raw Materials & Components: €0.00 Mil
  • GF Value™: €0.23 vs. price of €6.60 (2769.6% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the FRA:1S70 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cartesian Therapeutics Business Description

Other Exchanges RNAC:USA
Address 7495 New Horizon Way, Frederick, MD, USA, 21703
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
27GF Score

Get the complete analysis for FRA:1S70

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price
€0.23
GF Value